Association of @entity20637 polymorphisms with peginterferon efficacy in XXXX with HBeAg-positive in the Chinese population.

@entity1 @entity97 @entity20637 @entity71899 @entity1956 @entity6194 @entity71898 @entity71897 @entity454
AIMS: To investigate whether @entity20637 polymorphisms affect peginterferon alpha (PEG-IFN) efficacy in @entity6194 ( @entity6194 ) @entity1 using a tag- single nucleotide polymorphism (SNP) approach. METHODS: A total of 212 @entity1956 e antigen (HBeAg)-positive @entity1 treated with a 48weeks of PEG-IFN monotherapy were enrolled initially and 127 @entity1 were followed for 48weeks posttreatment. Genotype analysis was performed for 10 tag-SNPs in @entity20637 . RESULTS: The @entity454 ( @entity454 ) rate was 45.8% (97/212) and the sustained virological response (SVR) rate was 45.7% (58/127). Meanwhile, 35.4% (75/212) achieved HBeAg seroconversion at the end of treatment. In a multivariate analysis, the @entity71897 CC genotype was independently associated with @entity454 (OR 2.21, 95% CI 1.23-3.98, P=0.008) and SVR (OR 2.34, 95% CI 1.05-5.20, P=0.037) after adjustment for sex, age, @entity97 genotype, baseline levels of @entity97 DNA and ALT. Meanwhile, @entity71897 CC genotype were also independently associated with decline of HBsAg levels below 1500IU/mL at 12weeks of treatment (OR 2.52, 95% CI 1.01-6.29, P=0.047). Furthermore, three SNPs were found to be independently associated with HBeAg seroconversion at the end of treatment. (1) The @entity71898 CC genotype was independently associated with no HBeAg seroconversion (OR 0.52, 95% CI 0.29-0.95, P=0.034); (2) The @entity71899 TT genotype was independently associated with HBeAg seroconversion (OR 2.11, 95% CI 1.14-3.90, P=0.017); (3) The @entity71897 CC genotype was independently associated with HBeAg seroconversion (OR 2.36, 95% CI 1.26-4.42, P=0.007). CONCLUSIONS: Polymorphisms in @entity20637 are independently associated with treatment response to PEG-IFN among Chinese HBeAg-positive @entity6194 @entity1 .
